MC
RXRX icon

Moors & Cabot’s Recursion Pharmaceuticals RXRX Stock Holding History

Moors & Cabot’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$71.7K Buy
19,550
+6,950
+55% +$23.1K ﹤0.01% 940
2026
Q1 		$38.7K Sell
12,600
-15,150
-55% -$58.5K ﹤0.01% 918
2025
Q4 		$113K Sell
27,750
-896
-3% -$4.44K ﹤0.01% 886
2025
Q3 		$140K Sell
28,646
-15,904
-36% -$83.5K 0.01% 866
2025
Q2 		$225K Buy
44,550
+680
+2% +$3.34K 0.01% 760
2025
Q1 		$232K Buy
+43,870
New +$320K 0.01% 729
2024
Q2 		– Sell
-13,500
Closed -$135K – 930
2024
Q1 		$135K Buy
+13,500
New +$150K 0.01% 847

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Moors & Cabot's RXRX Position: Q2 2026 in Review

Moors & Cabot increased its Recursion Pharmaceuticals (RXRX) stake by 55% in Q2 2026, buying an estimated $23.1K and bringing the position to 19,550 shares worth $71.7K. The position accounts for ﹤0.01% of the portfolio, ranked #940.

Moors & Cabot first reported a position in RXRX in Q1 2024 and has held it in 7 quarters since. The position peaked at $232K in Q1 2025. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Moors & Cabot held 19,550 shares of Recursion Pharmaceuticals worth $71.7K as of Q2 2026.
  • Moors & Cabot bought 6,950 Recursion Pharmaceuticals shares in Q2 2026, an estimated $23.1K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Moors & Cabot's portfolio in Q2 2026, its #940 holding.
  • Moors & Cabot first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 7 quarters since.
  • Moors & Cabot's Recursion Pharmaceuticals position peaked at $232K in Q1 2025.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Moors & Cabot's 13F filing for Q2 2026, filed 10 Aug 2026.